Isis CEO Receives Prestigious Lifetime Achievement Award

CEO and Chairman of the Board of Directors of Isis Pharmaceuticals, Stanley T. Crooke, PhD, MD was awarded the prestigious SCRIP Lifetime Achievement Award in biotechnology and pharmaceuticals. The award recognizes Crooke’s innovative spirit and dedication to drug discovery and development. As a licensed physician, scientist and entrepreneur, Crooke has been dedicated to this mission since the beginning of his career at Bristol Labs, where he played a part in establishing the anti-cancer drug discovery and development program; at GlaxoSmithKline where he oversaw worldwide R&D, and was involved in commercialization of numerous drugs; and as founder and leader of Isis where he led the development of a new platform for drug discovery.

Senior Communications Executive Joins GPhA

Generic Pharmaceutical Association (GPhA), an organization that represents generic and bulk pharmaceutical manufacturers, hired Terry Bazyluk as Vice President for Communications. Bazyluk has a prestigious background working in various communications roles for trade associations, corporate CEOs and presidential cabinet secretaries, Madeleine Albright, Colin Powell and Robert Reich. He has a legal background and experience working on two winning presidential campaigns. Bazyluk joins GPhA after nearly 10 years serving as Head of Executive Communications at Freddie Mac. During his 25-year career, he has gained broad expertise with a range of science, technology and policy subjects. In his new role, Bazyluk will leverage his exceptional writing, messaging and advocacy talent to promote the contributions of generic medicines to patients and the healthcare system.


A clinical-stage biopharma company focused on cardio-renal, gastrointestinal and metabolic disease hired Jeremy S. Caldwell, PhD, as Executive Vice President and Chief Scientific Officer. Caldwell brings 20 years of experience in drug discovery and development at several major pharma companies and in the biotechnology industry as an entrepreneur.


A marketing firm serving pharma companies as well as other industries promoted Melissa Johnston to President. Johnston will be responsible for all agency functions and executing the company’s vision and strategy, as well as overseeing sales and marketing.

CMC Biologics

A contract manufacturing organization specializing in therapeutic proteins appointed Joseph Wypych as General Manager of its Seattle facility. He will manage site operations of CMC Biologics’ clinical and commercial manufacturing facility. Wypych brings more than 20 years biopharma expertise in process development and manufacturing. Prior to joining CMC, he served as Plant Manager at Baxter BioScience.


Barbara Holland is now Director of Business Development for the South East Region for Formex, a contract development and manufacturer of oral and topical dosage.

With more than 13 years experience in the pharma industry, Holland most recently served at Pharmaceutics International. Holland’s knowledge and expertise will strengthen Formex’s ability to build partnerships in the industry.

Institut Pasteur

A non-profit research institution in science, medicine and public health added two new members to its team: Isabelle Buckle, PhD as EVP, Research Applications and Industrial Partnerships Department and Pierre Legrain, PhD as EVP, Academic Development and Grant Office Direction. These two strategic positions were created to strengthen the links between Institut Pasteur research, academia and private industry.

Intrexon Corp.

A synthetic biotechnology company, appointed Peter Emtage, PhD as Vice President, Synthetic Immunology. In his new role, Emtage will focus on further advancing the company’s oncology and immunology platforms. Emtage brings over 16 years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases and inflammation to Intrexon.


A global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries hired Mark R. Hembarsky as Vice President, Logistics, North America. His appointment brings extensive pharmaceutical and operational experience to Marken as he is a 34-year veteran in the pharma industry. Hembarsky has held executive roles at GlaxoSmithKline, Valeant Pharmaceuticals and most recently Aptuit.


This oral biologics developer hired Peter Mueller, PhD as President of R&D and Chief Scientific Officer. In his new role, Mueller will lead Pronutria’s efforts to discover and develop products to maintain health and treat a variety of serious medical conditions across a wide spectrum of indications. Before joining Pronutria, Mueller served as Senior Vice President, Research and Development for Boehringer Ingelheim and was instrumental in the global development of Spiriva, Combivent and Atrovent.

Relmada Therapeutics

A clinical-stage pharmaceutical company based in New York, named Christine Silverstein as Director of Investor Relations. Silverstein brings more than 10 years experience in corporate communications and financial services where she most recently served as the Vice President of Corporate Development for PlasmaTech BioPharmaceuticals, Inc. (formerly Access Pharmaceuticals). She also served as Managing Director at SCO Financial Group, a New York-based life science financial advisory firm.

Rigel Pharmaceuticals

Named Raul Rodriguez as the new Chief Executive Officer. Since joining Rigel in 2000, Rodriguez has been pivotal in developing relationships with industry leaders and observers, speaking on behalf of the company and the industry at major events.

StoneArch Creative

Promoted Nikos Katopodis to Director of Agency Partnerships. Prior to his new role, Katopodis served as Director of Client Services for StoneArch. He will now develop new client relationships, as well as forge alliances and partnerships with outside resources including strategic consultants and specialty vendors. Katopodis has also served in leadership roles at Surge Healthcare Communications, Area 23 and Concentric.

Surgical Specialties

A surgical instrument manufacturer added two new executives to its management team, Daniel Sutherby has joined as Chief Financial Officer and Brennan Marilla as Chief Commercial Officer. Before joining the company, Sutherby held various senior positions at both public and private medical device and diagnostic companies including IQuum, Abiomed and PerkinElmer. Marilla also brings a wealth of experience in medical device sales, sales management, product management and global marketing in companies including Medtronic and AngioDynamics, with her most recent tenure at Covidien.


You May Also Like

The Point of Care Marketing Association Welcomes CMI Media Group and Compas

The Point of Care Marketing Association (POCMA), a nonprofit organization to support the continued ...

Healthcare Watch September 2017

Brand Beat: Reimagining Celebrity Ad Spots Novartis recently aired a commercial for their psoriasis ...

Today’s Product Manager

Even as product managers stay the same they are always changing. That is one ...